Stephen Raben
Family Medicine · Fort Myers, FLNPI 1649228990
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 381 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 21.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,211 and has fallen 90.6% since, to $114 in 2025. Among family medicine clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 381 payments — averaging $13.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$471
- Lilly USA, LLC$355
- Pfizer$321
- Kowa Pharmaceuticals America, Inc.$272
- Novo Nordisk$254
- plus $2K from 29 others
What the payments were for
- Food & beverage$5,006100%
- Education$210%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 103 | $1,083 |
| AstraZeneca | 33 | $471 |
| Lilly USA, LLC | 27 | $355 |
| Pfizer | 39 | $321 |
| Kowa Pharmaceuticals America, Inc. | 23 | $272 |
| Novo Nordisk | 18 | $254 |
| E.r. Squibb & Sons, L.L.C. | 11 | $213 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $198 |
| Sanofi-aventis U.S. LLC | 11 | $184 |
| Astellas Pharma US Inc | 9 | $156 |
| Merck | 6 | $122 |
| Boehringer Ingelheim | 7 | $110 |
| Amgen | 7 | $106 |
| Novartis | 5 | $103 |
| Johnson & Johnson | 7 | $97 |
| Dexcom, Inc. | 6 | $92 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $86 |
| Bayer | 5 | $81 |
| GSK | 6 | $77 |
| Abbott | 4 | $76 |
| Nestle Healthcare Nutrition Inc. | 5 | $75 |
| Sanofi Pasteur Inc. | 4 | $74 |
| Axsome Therapeutics, Inc. | 2 | $55 |
| Esperion Therapeutics, Inc. | 3 | $52 |
| Amarin Pharma, Inc. | 2 | $49 |
| Biohaven Pharmaceuticals, Inc. | 3 | $45 |
| Corcept Therapeutics | 2 | $40 |
| Sumitomo Pharma America, Inc. | 3 | $39 |
| Sunovion Pharmaceuticals Inc. | 2 | $28 |
| Seqirus USA Inc | 2 | $26 |
| Arbor Pharmaceuticals, Inc. | 1 | $20 |
| Ironshore Pharmaceuticals Inc. | 1 | $18 |
| Optos, Inc. | 1 | $17 |
| Exact Sciences | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
How this compares
$5,027 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 50 | $41,908 |
| EliquisApixaban | 40 | $37,137 |
| OzempicSemaglutide | 31 | $36,470 |
| FarxigaDapagliflozin Propanediol | 34 | $30,050 |
| MyrbetriqMirabegron | 30 | $24,035 |
| JanuviaSitagliptin Phosphate | 15 | $17,742 |
| MounjaroTirzepatide | 13 | $13,409 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $9,028 |
| TradjentaLinagliptin | 13 | $8,600 |
| Xtampza ErOxycodone Myristate | 11 | $5,860 |
| Atorvastatin Calcium | 250 | $2,650 |
| Rosuvastatin Calcium | 182 | $2,637 |
| Levothyroxine Sodium | 222 | $2,284 |
| Omeprazole | 178 | $2,133 |
| Febuxostat | 11 | $2,080 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $110 | $50,50863 claims |
| PfizerEliquis | $321 | $37,13740 claims |
| Novo NordiskOzempic | $254 | $36,47031 claims |
| AstraZenecaFarxiga | $471 | $30,05034 claims |
| Astellas Pharma US IncMyrbetriq | $156 | $24,03530 claims |
| MerckJanuvia | $122 | $17,74215 claims |
| Lilly USA, LLCMounjaro | $355 | $13,40913 claims |
| GSKTrelegy Ellipta | $77 | $9,02814 claims |
| AbbVieSynthroid | $1,083 | $93717 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Fort Myers
- Shannon GreerFort Myers$93K
- Noah LeeOakland Park$1.2M
- Angela RosselotBelle Isle$977K
- Richard LappOrlando$702K
- Hal BrownVero Beach$477K
- Lisa EvansBoca Raton$473K
- Giovana Rene CrooksBoca Raton$407K
- Edward BraunSt Petersburg$364K
- Samuel GreenleePensacola$235K
- Kevin FitzgeraldStuart$198K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.